GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

The funding, which brings GSK’s expenditure in US manufacturing capabilities close to $1.3bn, will establish a new vaccines ...

GLAXOSMITHKLINE (GSK) has confirmed that its manufacturing operations will cease next year as its current contract with a ...

The site at Ulverston currently belongs to GlaxoSmithKline (GSK), which ... to establish the area as a "nationally-advanced manufacturing location". The proposals include "flexible office space ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in Singapore. GSK inked an antibody-drug conjugate deal with DualityBio and ...

GSK said the vast majority of the products will be for export to global markets, adding that the investment builds on the company’s existing network of nine UK manufacturing sites, employing ...

SINGAPORE - The expansion of British drugmaker GSK’s facility in Tuas has earned the title of Singapore’s largest vaccine production site based on a cumulative investment of some $850 million ...